中信里昂发布研报称，予阿里健康“跑赢大市”评级。报告指，阿里健康2025年3月底止财年度下半年收入符合预期，但由于市场及推广开支增长，利润未达预期。虽然流感带来的受益是短暂的，但原厂药销售从医院内流向制药公司应该会成为结构性增长动力。调整后净利润同比增22%，利润率为6%，低于预期的6.5%，主要原因是市场及推广开支高于预期。公司预计2026财年收入将增长5-10%，利润增长10-20%，反映调整...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.